Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2006 1
2010 2
2011 2
2012 8
2013 4
2014 7
2015 8
2016 19
2017 35
2018 69
2019 88
2020 163
2021 187
2022 191
2023 170
2024 180
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

995 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% confidence interval [CI], -13 to 18; P = 0.73 for superiority), showing noninferiority but not sup …
The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab gr …
Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Charles D, et al. Clin Exp Allergy. 2022 May;52(5):616-627. doi: 10.1111/cea.14112. Epub 2022 Mar 9. Clin Exp Allergy. 2022. PMID: 35174566 Free PMC article. Review.
RESULTS: A total of 21 studies examining biologicals in real-world settings were identified; they mostly focused on benralizumab and mepolizumab. The introduction of biologicals reduced the annualzsed exacerbation rate significantly by -3.79 (95% confidence interval [CI] - …
RESULTS: A total of 21 studies examining biologicals in real-world settings were identified; they mostly focused on benralizumab and …
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T, Lassiter G, Chen ML, Alexander GC, Keet C, Hong H, Akenroye A. Nopsopon T, et al. J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17. J Allergy Clin Immunol. 2023. PMID: 36538979 Free PMC article.
Tezepelumab (relative risk: 0.63; 95% credible interval [CI]: 0.46-0.86) was associated with significantly lower exacerbation rates than benralizumab and larger improvements in FEV(1) compared to mepolizumab (mean difference [MD]: 66; 95% CI: -33 to 170) and benralizuma …
Tezepelumab (relative risk: 0.63; 95% credible interval [CI]: 0.46-0.86) was associated with significantly lower exacerbation rates than …
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter or greater. ...RESULTS: In GAL …
The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizu …
Benralizumab (Fasenra).
[No authors listed] [No authors listed] 2022 Nov. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2022 Nov. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 35951862 Free Books & Documents. Review.
This sheet is about exposure to benralizumab in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider....
This sheet is about exposure to benralizumab in pregnancy and while breastfeeding. This information should not take the place of medi …
Benralizumab (Fasenra).
[No authors listed] [No authors listed] 2022 Nov. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2022 Nov. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 35951863 Free Books & Documents. Review.
Esta hoja trata sobre la exposicion a benralizumab en el embarazo y durante la lactancia. Esta informacion no debe usarse como un sustituto de la atencion medica o los consejos de su proveedor de atencion de salud....
Esta hoja trata sobre la exposicion a benralizumab en el embarazo y durante la lactancia. Esta informacion no debe usarse como un sus …
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, Werkström V. Bachert C, et al. J Allergy Clin Immunol. 2022 Apr;149(4):1309-1317.e12. doi: 10.1016/j.jaci.2021.08.030. Epub 2021 Sep 29. J Allergy Clin Immunol. 2022. PMID: 34599979 Clinical Trial.
Patients were randomized 1:1 to treatment with benralizumab 30 mg or placebo every 4 weeks for the first 3 doses and every 8 weeks thereafter. ...RESULTS: The study population comprised 413 randomized patients (207 in the benralizumab group and 206 in the placebo gr …
Patients were randomized 1:1 to treatment with benralizumab 30 mg or placebo every 4 weeks for the first 3 doses and every 8 weeks th …
Benralizumab for eosinophilic granulomatosis with polyangiitis.
Cottu A, Groh M, Desaintjean C, Marchand-Adam S, Guillevin L, Puechal X, Beaumesnil S, Lazaro E, Samson M, Taille C, Durel CA, Diot E, Nicolas S, Guilleminault L, Ebbo M, Cathebras P, Dupin C, Yildiz H, Belfeki N, Pugnet G, Chauvin P, Jouneau S, Lifermann F, Martellosio JP, Cottin V, Terrier B; French Vasculitis Study Group. Cottu A, et al. Ann Rheum Dis. 2023 Dec;82(12):1580-1586. doi: 10.1136/ard-2023-224624. Epub 2023 Aug 7. Ann Rheum Dis. 2023. PMID: 37550002
BACKGROUND: Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis ( …
BACKGROUND: Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eo …
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Agache I, et al. Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24. Allergy. 2020. PMID: 32034960
Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. ...Benralizumab, dupilumab and mepolizumab reduce the daily …
Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabe …
Benralizumab.
[No authors listed] [No authors listed] 2024 Oct 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Oct 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000011 Free Books & Documents. Review.
No information is available on the clinical use of benralizumab during breastfeeding. Because benralizumab is a large protein molecule with a molecular weight of about 150,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially dest …
No information is available on the clinical use of benralizumab during breastfeeding. Because benralizumab is a large protein …
995 results